Clinical Trials
Cancer research helps find new ways to prevent, diagnose, treat, and manage all stages of cancer. Clinical trials are an important part of this process. When you take part in a clinical trial, you help researchers learn more about cancer and help make cancer care better for future patients.
To learn what your clinical trial options are, ask your oncologist whether there are any clinical trials that might be a good fit for you.
Learn More:
Visit the
It Starts with Me website for general information about clinical trials.
For more detailed links and resources see
Clinical Trials Resources page.
Clinical Trials available at THP
Disease Site: GI - GASTRIC or GASTROESOPHAGEAL JUNCTION (GEJ)
Study: DS8201-724 (DESTINY-GASTRIC05)
Sponsor: DAIICHI SANKYO INC.
Principal Investigator: Dr. Elan Panov
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-Line Metastatic HER2-Positive Gastric or GEJ Cancer
clinicaltrials.gov Link:
NCT06731478
Disease Site: GI - HEPATOCELLULAR
Study: HE.2 (SLIDE-HCC)
Sponsor: CCTG
Principal Investigator: Dr. Mala Bahl
A Phase II Study of Stride (Durvalumab + Tremelimumab) with Lenvatinib Versus Stride Alone in Patients with Unrestectable Hepatocellular Carcinoma
clinicaltrials.gov Link:
NCT06880523
Disease Site: GU - PROSTATE
Study: PCS XI
Sponsor: CHU DE QUEBEC - LAVAL UNIVERSITY
Principal Investigator: Dr. Sarah Rauth
Pelvic nodes Ultra-Hypo Fractionated versus conventionally fractionated IMRT with HDR brachytherapy boost in prostate cancer: A collaborative multi-institutional non-inferiority phase 3 trial.
clinicaltrials.gov Link:
NCT05820633
RADIATION
Disease Site: GU - PROSTATE
Study: PR.24
(ASCENDE-SBRT)
Sponsor: CCTG
Principal Investigator: Dr. Jasper Yuen
Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost in Patients with Unfavourable Risk Localized Prostate Cancer
clinicaltrials.gov Link:
NCT06235697
Disease Site: GU - PROSTATE
Study: PR.26
(TRIPLE-SWITCH)
Sponsor: CCTG
Principal Investigator: Dr. Daniel Yokom
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
clinicaltrials.gov Link:
NCT06592924
Disease Site: GU - PROSTATE
Study: MK-5684-004 (OMAHA-004)
Sponsor: Merck
Principal Investigator: Dr. Daniel Yokom
Protocol: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer(mCRPC) Post One NHA
clinicaltrials.gov Link:
NCT06136650
Disease Site: GYNE - ADJUVANT ENDOMETRIAL
Study: EN.10
Sponsor: CCTG
Principal Investigator: Dr. Kate Pulman
A Phase II Study of Tailored Adjuvant Therapy in Pole-mutated And P53-wildtype/SNMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
SUBSTUDY A:
RAINBO POLEmut-BLUE: Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) TransPORTEC platform trials
SUBSTUDY B:
Tailored Adjuvant Therapy in p53-Wildtype/NSMP Early Stage Endometrial Cancer (TAPER)
clinicaltrials.gov Link:
NCT05640999
SURG / RADIATION
Disease Site: GYNE - OVARIAN
Study: MK-2870-022 (TROFUSE-022)
Sponsor: Merck
Principal Investigator: Dr. Tomer Feigenberg
Protocol: A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer
clinicaltrials.gov Link:
NCT06824467
Disease Site: LUNG - METASTATIC NSCLC
Study: MK-2870-007
Sponsor: Merck
Principal Investigator: Dr. Daniel Yokom
A randomized, open-label, phase 3 study of MK-2870 in combination with pembrolizumab compared to pembrolizumab monotherapy in the first-line treatment of participants with metastatic non-small cell lung cancer with PD-L1 TPS greater than or equal to 50% (TroFuse-007)
clinicaltrials.gov Link:
NCT06170788
